Ignite Creation Date:
2025-12-24 @ 3:14 PM
Ignite Modification Date:
2025-12-25 @ 9:56 PM
Study NCT ID:
NCT05645692
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-10-31
First Post:
2022-11-28
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'interventionBrowseModule': {'meshes': [{'id': 'C000594389', 'term': 'atezolizumab'}, {'id': 'C000730814', 'term': 'Tiragolumab'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 204}}, 'statusModule': {'overallStatus': 'ACTIVE_NOT_RECRUITING', 'startDateStruct': {'date': '2023-04-13', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-10', 'completionDateStruct': {'date': '2026-03-20', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-10-30', 'studyFirstSubmitDate': '2022-11-28', 'studyFirstSubmitQcDate': '2022-12-07', 'lastUpdatePostDateStruct': {'date': '2025-10-31', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2022-12-09', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-03-20', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Incidence and Severity of Adverse Events', 'timeFrame': 'Up to approximately 30 months'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Urothelial Cancer']}, 'descriptionModule': {'briefSummary': 'This study will evaluate the safety of tobemstomig alone or in combination with tiragolumab compared with atezolizumab in participants with previously untreated, locally advanced or metastatic urothelial cancer (mUC) who are ineligible to receive a platinum containing chemotherapy.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2\n* Histologically or cytologically documented locally advanced or metastatic transitional cell carcinoma (TCC) of the urothelium. Participants with squamous, sarcomatoid, micropapillary, and glandular variant histologies are eligible for inclusion in the study, provided that a urothelial component is present in the tumor specimen. Participants with other variant histologies or pure variant histologies are not eligible for inclusion in this study\n* Ineligible ("unfit") to receive platinum-based chemotherapy\n* No prior chemotherapy for inoperable locally advanced or metastatic or recurrent urothelial carcinoma (UC)\n* Measurable disease; at least one measurable lesion as defined by response evaluation criteria in solid tumors, version 1.1 (RECIST v1.1)\n* Availability of a representative leftover tumor specimen that is suitable for determination of PD-L1 status as assessed by a central laboratory\n* Adequate hematologic and end organ function\n* Negative for hepatitis B and hepatitis C virus (HCV)\n* Adequate cardiovascular function\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding\n* GFR \\<15 mL/min/1.73 m2\n* Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases\n* History of leptomeningeal disease\n* Uncontrolled tumor-related pain\n* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures\n* Uncontrolled or symptomatic hypercalcemia\n* Active or history of autoimmune disease or immune deficiency\n* History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan\n* Active tuberculosis (TB) or acute Epstein-Barr virus (EBV)\n* Significant cardiovascular/cerebrovascular disease within 3 months prior to initiation of study treatment\n* Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study\n* History of another primary malignancy other than urothelial carcinoma within 2 years prior to initiation of study treatment, with the exception of malignancies with a negligible risk of metastasis or death\n* Severe infection within 4 weeks prior to initiation of study treatment\n* Treatment with therapeutic oral or intravenous antibiotics within 2 weeks prior to initiation of study treatment. Participants receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or chronic obstructive pulmonary disease \\[COPD\\] exacerbation), or who are receiving oral antibiotics to treat a urinary tract infection are eligible for the study\n* Prior allogeneic stem cell or solid organ transplantation\n* Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during treatment or within 5 months after the final dose of atezolizumab, 4 months after the final dose of tobemstomig, or 90 days after the final dose of tiragolumab\n* Current treatment with anti-viral therapy for HBV\n* Treatment with any approved anti-cancer therapy, including chemotherapy or hormonal therapy, within 3 weeks prior to initiation of study treatment\n* Treatment with investigational therapy within 4 weeks or 5 drug-elimination half-lives (whichever is longer) prior to initiation of study treatment\n* Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-TIGIT and anti-LAG3 therapeutic antibodies or pathways targeting agents\n* Treatment with systemic immunostimulatory agents within 4 weeks or 5 drug-elimination half-lives prior to initiation of study treatment\n* Treatment with systemic immunosuppressive medication within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during study treatment\n* History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins'}, 'identificationModule': {'nctId': 'NCT05645692', 'briefTitle': 'A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer', 'organization': {'class': 'INDUSTRY', 'fullName': 'Hoffmann-La Roche'}, 'officialTitle': 'A Phase II, Randomized, Multicenter, Open-Label, Controlled Study of Tobemstomig Alone or in Combination With Tiragolumab Versus Atezolizumab in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer Who Are Ineligible for Platinum-Containing Chemotherapy', 'orgStudyIdInfo': {'id': 'BO44157'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'ACTIVE_COMPARATOR', 'label': 'Arm A', 'description': 'Participants will receive intravenous (IV) atezolizumab every 3 weeks (Q3W).', 'interventionNames': ['Drug: Atezolizumab']}, {'type': 'EXPERIMENTAL', 'label': 'Arm B', 'description': 'Participants will receive IV tobemstomig Q3W.', 'interventionNames': ['Drug: Tobemstomig']}, {'type': 'EXPERIMENTAL', 'label': 'Arm C', 'description': 'Participants will receive IV tobemstomig + IV tiragolumab Q3W.', 'interventionNames': ['Drug: Tobemstomig', 'Drug: Tiragolumab']}], 'interventions': [{'name': 'Atezolizumab', 'type': 'DRUG', 'description': 'Participants will receive 1200 mg IV atezolizumab Q3W.', 'armGroupLabels': ['Arm A']}, {'name': 'Tobemstomig', 'type': 'DRUG', 'otherNames': ['RO7247669'], 'description': 'Participants will receive 600 mg IV tobemstomig Q3W.', 'armGroupLabels': ['Arm B', 'Arm C']}, {'name': 'Tiragolumab', 'type': 'DRUG', 'description': 'Participants will receive 600 mg IV tiragolumab Q3W.', 'armGroupLabels': ['Arm C']}]}, 'contactsLocationsModule': {'locations': [{'zip': '44106', 'city': 'Cleveland', 'state': 'Ohio', 'country': 'United States', 'facility': 'Cleveland Clinic', 'geoPoint': {'lat': 41.4995, 'lon': -81.69541}}, {'zip': '77030', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'MD Anderson Cancer Center', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '2113', 'city': 'Macquarie Park', 'state': 'New South Wales', 'country': 'Australia', 'facility': 'Macquarie University Hospital', 'geoPoint': {'lat': -33.78105, 'lon': 151.12757}}, {'zip': '5112', 'city': 'Adelaide', 'state': 'South Australia', 'country': 'Australia', 'facility': 'Lyell McEwin Hospital', 'geoPoint': {'lat': -34.92866, 'lon': 138.59863}}, {'zip': '5037', 'city': 'Kurralta Park', 'state': 'South Australia', 'country': 'Australia', 'facility': 'ICON Cancer Care Adelaide', 'geoPoint': {'lat': -34.95142, 'lon': 138.56702}}, {'zip': '80440-220', 'city': 'Curitiba', 'state': 'Paraná', 'country': 'Brazil', 'facility': 'Hospital Universitario Evangelico De Curitiba', 'geoPoint': {'lat': -25.42778, 'lon': -49.27306}}, {'zip': '90035-903', 'city': 'Porto Alegre', 'state': 'Rio Grande do Sul', 'country': 'Brazil', 'facility': 'Hospital das Clinicas - UFRGS', 'geoPoint': {'lat': -30.03283, 'lon': -51.23019}}, {'zip': '76834-899', 'city': 'Porto Velho', 'state': 'Rondônia', 'country': 'Brazil', 'facility': 'Hospital de Amor Amazônia', 'geoPoint': {'lat': -8.76194, 'lon': -63.90389}}, {'zip': '09060-650', 'city': 'Santo André', 'state': 'São Paulo', 'country': 'Brazil', 'facility': '*X*CEPHO - Centro de Estudos e Pesquisas em Hematologia e Oncologia', 'geoPoint': {'lat': -23.66389, 'lon': -46.53833}}, {'zip': '01323-903', 'city': 'São Paulo', 'state': 'São Paulo', 'country': 'Brazil', 'facility': 'Hospital Alemao Oswaldo Cruz', 'geoPoint': {'lat': -23.5475, 'lon': -46.63611}}, {'zip': '100142', 'city': 'Beijing', 'country': 'China', 'facility': 'Beijing Cancer Hospital', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}, {'zip': '610047', 'city': 'Chengdu', 'country': 'China', 'facility': 'West China Hospital - Sichuan University', 'geoPoint': {'lat': 30.66667, 'lon': 104.06667}}, {'zip': '510060', 'city': 'Guangzhou', 'country': 'China', 'facility': 'Sun yat-sen University Cancer Center', 'geoPoint': {'lat': 23.11667, 'lon': 113.25}}, {'zip': '200025', 'city': 'Shanghai', 'country': 'China', 'facility': 'Ruijin Hospital, Shanghai Jiaotong University School of Medicine', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}, {'zip': '8200', 'city': 'Aarhus N', 'country': 'Denmark', 'facility': 'Aarhus Universitetshospital', 'geoPoint': {'lat': 56.20367, 'lon': 10.17317}}, {'zip': '2730', 'city': 'Herlev', 'country': 'Denmark', 'facility': 'Herlev Hospital', 'geoPoint': {'lat': 55.72366, 'lon': 12.43998}}, {'zip': '69373', 'city': 'Lyon', 'country': 'France', 'facility': 'Centre Leon Berard', 'geoPoint': {'lat': 45.74906, 'lon': 4.84789}}, {'zip': '94800', 'city': 'Villejuif', 'country': 'France', 'facility': 'Gustave Roussy', 'geoPoint': {'lat': 48.7939, 'lon': 2.35992}}, {'zip': '06120', 'city': 'Halle', 'country': 'Germany', 'facility': 'Krankenhaus Martha-Maria Halle-Dölau, Klinik für Urologie', 'geoPoint': {'lat': 51.48158, 'lon': 11.97947}}, {'zip': '20246', 'city': 'Hamburg', 'country': 'Germany', 'facility': 'Martini-Klinik am UKE GmbH', 'geoPoint': {'lat': 53.55073, 'lon': 9.99302}}, {'zip': '115 28', 'city': 'Athens', 'country': 'Greece', 'facility': 'Alexandras General Hospital of Athens', 'geoPoint': {'lat': 37.98376, 'lon': 23.72784}}, {'zip': '124 62', 'city': 'Chaïdári', 'country': 'Greece', 'facility': 'Attikon University General Hospital', 'geoPoint': {'lat': 38.01135, 'lon': 23.66597}}, {'zip': '54007', 'city': 'Thessaloniki', 'country': 'Greece', 'facility': 'Theageneio Hospital', 'geoPoint': {'lat': 40.64072, 'lon': 22.93493}}, {'zip': '70124', 'city': 'Bari', 'state': 'Apulia', 'country': 'Italy', 'facility': 'A.O. Universitaria Ospedale Consorziale Policlinico Di Bari', 'geoPoint': {'lat': 41.12066, 'lon': 16.86982}}, {'zip': '80131', 'city': 'Napoli', 'state': 'Campania', 'country': 'Italy', 'facility': 'Istituto Nazionale Tumori Irccs Fondazione G. Pascale', 'geoPoint': {'lat': 40.87618, 'lon': 14.5195}}, {'zip': '40138', 'city': 'Bologna', 'state': 'Emilia-Romagna', 'country': 'Italy', 'facility': 'Azienda Ospedaliero-Universitaria S.Orsola-Malpighi', 'geoPoint': {'lat': 44.49381, 'lon': 11.33875}}, {'zip': '47014', 'city': 'Meldola', 'state': 'Emilia-Romagna', 'country': 'Italy', 'facility': 'IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola', 'geoPoint': {'lat': 44.12775, 'lon': 12.0626}}, {'zip': '00168', 'city': 'Rome', 'state': 'Lazio', 'country': 'Italy', 'facility': 'Policlinico Universitario "Agostino Gemelli"', 'geoPoint': {'lat': 41.89193, 'lon': 12.51133}}, {'zip': '20132', 'city': 'Milan', 'state': 'Lombardy', 'country': 'Italy', 'facility': 'Irccs Ospedale San Raffaele', 'geoPoint': {'lat': 45.46427, 'lon': 9.18951}}, {'zip': '05100', 'city': 'Terni', 'state': 'Umbria', 'country': 'Italy', 'facility': 'Azienda Ospedaliera S. Maria - Terni', 'geoPoint': {'lat': 42.56335, 'lon': 12.64329}}, {'zip': '35128', 'city': 'Padua', 'state': 'Veneto', 'country': 'Italy', 'facility': 'IRCCS Istituto Oncologico Veneto (IOV)', 'geoPoint': {'lat': 45.40797, 'lon': 11.88586}}, {'zip': '03100', 'city': 'Mexico City', 'state': 'Mexico CITY (federal District)', 'country': 'Mexico', 'facility': 'Health Pharma Professional Research', 'geoPoint': {'lat': 19.42847, 'lon': -99.12766}}, {'zip': '75-581', 'city': 'Koszalin', 'country': 'Poland', 'facility': 'Szpital Wojewódzki im. Miko?aja Kopernika', 'geoPoint': {'lat': 54.19438, 'lon': 16.17222}}, {'zip': '31-501', 'city': 'Krakow', 'country': 'Poland', 'facility': 'Szpital Uniwersytecki w Krakowie', 'geoPoint': {'lat': 50.06143, 'lon': 19.93658}}, {'zip': '60-192', 'city': 'Późna', 'country': 'Poland', 'facility': 'Pratia Poznan', 'geoPoint': {'lat': 51.84442, 'lon': 14.61868}}, {'zip': '04-073', 'city': 'Warsaw', 'country': 'Poland', 'facility': 'Szpital Grochowski im. dr med. Rafa?a Masztaka Sp. z o.o.', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'city': 'Gyeonggi-do', 'country': 'South Korea', 'facility': 'Seoul National University Bundang Hospital', 'geoPoint': {'lat': 37.58944, 'lon': 126.76917}}, {'zip': '21565', 'city': 'Incheon', 'country': 'South Korea', 'facility': 'Gachon University Gil Medical Center', 'geoPoint': {'lat': 37.45646, 'lon': 126.70515}}, {'zip': '03080', 'city': 'Seoul', 'country': 'South Korea', 'facility': 'Seoul National University Hospital', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '03722', 'city': 'Seoul', 'country': 'South Korea', 'facility': 'Severance Hospital, Yonsei University', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '05505', 'city': 'Seoul', 'country': 'South Korea', 'facility': 'Asan Medical Center', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '06351', 'city': 'Seoul', 'country': 'South Korea', 'facility': 'Samsung Medical Center', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '08035', 'city': 'Barcelona', 'country': 'Spain', 'facility': "Vall d'Hebron Institute of Oncology (VHIO), Barcelona", 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '08908', 'city': 'Barcelona', 'country': 'Spain', 'facility': 'Institut Catala d Oncologia Hospital Duran i Reynals', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '28040', 'city': 'Madrid', 'country': 'Spain', 'facility': 'Hospital Universitario Clínico San Carlos', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '28041', 'city': 'Madrid', 'country': 'Spain', 'facility': 'Hospital Universitario 12 de Octubre', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '28046', 'city': 'Madrid', 'country': 'Spain', 'facility': 'Hospital Universitario La Paz', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '28050', 'city': 'Madrid', 'country': 'Spain', 'facility': 'Hospital de Madrid Norte Sanchinarro- Centro Integral Oncologico Clara Campal', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '01220', 'city': 'Adana', 'country': 'Turkey (Türkiye)', 'facility': 'Adana Baskent University Medical Faculty', 'geoPoint': {'lat': 36.98615, 'lon': 35.32531}}, {'zip': '06800', 'city': 'Ankara', 'country': 'Turkey (Türkiye)', 'facility': 'Ankara City Hospital', 'geoPoint': {'lat': 39.91987, 'lon': 32.85427}}, {'zip': '22030', 'city': 'Edirne', 'country': 'Turkey (Türkiye)', 'facility': 'Trakya Universitesi Tip Fakultesi, Medikal Onkoloji Bilim Dali, Balkan Yerleskesi', 'geoPoint': {'lat': 41.67719, 'lon': 26.55597}}, {'zip': '35101', 'city': 'Izmir', 'country': 'Turkey (Türkiye)', 'facility': 'Izmir Medical Point Hospital', 'geoPoint': {'lat': 38.41273, 'lon': 27.13838}}, {'zip': '34722', 'city': 'Kadiköy', 'country': 'Turkey (Türkiye)', 'facility': 'Goztepe Prof.Dr. Suleyman Yalcin City Hospital', 'geoPoint': {'lat': 41.06639, 'lon': 41.01294}}, {'zip': 'E1 2ES', 'city': 'London', 'country': 'United Kingdom', 'facility': 'Barts and the London NHS Trust', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'PR2 9HT', 'city': 'Preston', 'country': 'United Kingdom', 'facility': 'Royal Preston Hosptial', 'geoPoint': {'lat': 53.76282, 'lon': -2.70452}}, {'zip': 'SM2 5PT', 'city': 'Sutton', 'country': 'United Kingdom', 'facility': 'Royal Marsden Hospital (Sutton)', 'geoPoint': {'lat': 51.35, 'lon': -0.2}}], 'overallOfficials': [{'name': 'Clinical Trials', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Hoffmann-LaRoche'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'YES', 'description': "For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data\\_sharing"}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Hoffmann-La Roche', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}